Boehringer

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

Retrieved on: 
Wednesday, September 27, 2023
CABG, Percutaneous coronary intervention, Anticoagulant, International, Bleeding, Intraparenchymal hemorrhage, CET, Boehringer, Dabigatran, STAR, EACTS, Edoxaban, Acute coronary syndrome, International Star Registry, Cytokine adsorbing column, CTD, Research, AstraZeneca, Professional corporation, Eli Lilly, Clopidogrel, DOAC, Boehringer Ingelheim, Incidence, Bayer, Neurosurgery, International Safe Harbor Privacy Principles, Patient, Risk, European Heart Journal, Daiichi Sankyo, Blood, Rivaroxaban, Annual general meeting, Cytosorbents Corporation, United Kingdom, BMS, Cardiology, European Association for Cardio-Thoracic Surgery, Starship Enterprise, Trauma, Ticagrelor, ATR, Pfizer, Birth control, Pharmaceutical industry, Dentistry, Janssen, Aorta, Sanofi

The International STAR Registry captures high fidelity data on real-world clinical use and associated clinical outcomes using CytoSorb® for antithrombotic drug removal (ATR) in the acute hospital setting.

Key Points: 
  • The International STAR Registry captures high fidelity data on real-world clinical use and associated clinical outcomes using CytoSorb® for antithrombotic drug removal (ATR) in the acute hospital setting.
  • The STAR Registry, not to be confused with the completed U.S. and Canada STAR-T pivotal trial, is enrolling ahead of internal projections with plans for ongoing presentations at large, international conferences.
  • The first registry analysis entitled, “ Insights from the International Safe and Timely Antithrombotic Removal (STAR) Registry ” was presented at the EuroPCR conference in May 2023, the largest interventional cardiology conference in the E.U., attracting 11,500+ participants this year.
  • It also includes, for the first time, data on patients being treated with CytoSorb to reduce seven different antithrombotic medications.

Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim’s Upcoming Transforming Science Day: Europe

Retrieved on: 
Tuesday, September 19, 2023
Science, Business development, Partnership, Boehringer, OBT, Francis Crick Institute, Boehringer Ingelheim, ADC, BST, Fine chemical

Oxford, UK, San Jose, Calif., 19th September 2023 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, announces that its Chief Executive Officer, Christian Rohlff, will participate in the panel discussion titled “It takes a village: A holistic approach to external innovation” at Boehringer Ingelheim’s upcoming Transforming Science Day: Europe.

Key Points: 
  • Oxford, UK, San Jose, Calif., 19th September 2023 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, announces that its Chief Executive Officer, Christian Rohlff, will participate in the panel discussion titled “It takes a village: A holistic approach to external innovation” at Boehringer Ingelheim’s upcoming Transforming Science Day: Europe.
  • The panel discussion will take place on 2 October 2023 at 13:15 British Summer Time (BST) in London.
  • Transforming Science Day is an event developed and funded by Boehringer Ingelheim.
  • The Transforming Science Day: Europe event will be hosted at The Francis Crick Institute, in London, and will also be streamed live on LinkedIn from 13:00 to 16:00 (BST).

Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.

Retrieved on: 
Thursday, September 14, 2023
Amgen, Boehringer, Boehringer Ingelheim, Special, Prescription, Gastroenterology, Rheumatology, Research, Ambiguity, HCP, Novartis, Dermatology, AbbVie, Risk, DAW, Biocon, FDA, Fine chemical, Pharmaceutical industry, Adalimumab, Tomorrow

This in-depth research delved into their overarching sentiments, experiences, adoption rates, and future expectations regarding the ten newly launched adalimumab biosimilar offerings.

Key Points: 
  • This in-depth research delved into their overarching sentiments, experiences, adoption rates, and future expectations regarding the ten newly launched adalimumab biosimilar offerings.
  • The vast majority of survey participants exhibit general awareness of the growing availability of multiple adalimumab biosimilars.
  • Of note, gastroenterologists and dermatologists report notable wave-over-wave increased adoption of Amjevita, while rheumatologists’ overall biosimilar adoption has been more tepid.
  • Future projections reveal prescriber ambiguity and potential uncertainty regarding any of the recently launched biosimilars catching up to Amjevita.

Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors

Retrieved on: 
Wednesday, July 5, 2023
Amgen, Boehringer, University, Central Waqf Council, Marketing, Audit committee, Medication, Geographic atrophy, Metabolic disorder, David Berry (inventor), Washington State University College of Pharmacy and Pharmaceutical Sciences, Eli Lilly, Strategic Advisory Board for Intellectual Property Policy, Boehringer Ingelheim, Neuroscience, Plasma protein binding, International business, Otsuka Pharmaceutical, Akari, Eli Lilly and Company, Therapy, American University in Cairo, Pharmaceutical industry, Pharmacy

NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of industry veteran Wa’el Hashad to the Akari Board of Directors as an independent director.

Key Points: 
  • NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of industry veteran Wa’el Hashad to the Akari Board of Directors as an independent director.
  • “I am pleased to welcome Wa’el to our Board of Directors” said Ray Prudo, M.D., Akari Chairman.
  • Avanir was acquired by Otsuka Pharmaceutical, and Mr. Hashad led the company’s full integration into Otsuka’s United States operations.
  • He held the position of the Chairman of the Strategic Advisory Board at Morningside Biopharma and is currently a member of the Board of California Life Sciences.

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

Retrieved on: 
Wednesday, May 10, 2023
Maintenance, Obesity, Boehringer, Therapy, Heart failure, Chronic kidney disease, Prevalence, Hepatology, Liver disease, Weight loss, Boehringer Ingelheim, Patient, American Diabetes Association, CRM, Overweight, Zealand Pharma, Pharmaceutical industry

The phase II clinical trial evaluating the effect of different doses of the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes (NCT04667377) met its primary endpoint.

Key Points: 
  • The phase II clinical trial evaluating the effect of different doses of the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes (NCT04667377) met its primary endpoint.
  • “Obesity is one of many cardio-renal-metabolic diseases, which together represent one of the fastest growing health challenges worldwide.
  • Obesity is a major global health challenge, and the worldwide prevalence has more than doubled over the past four decades11.
  • The World Obesity Federation predicts that by 2025, 2.7 billion adults could be living with obesity or overweight, placing a high burden on individuals, healthcare systems and society11.

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Retrieved on: 
Tuesday, May 9, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Tissue, Graft-versus-host disease, Heart, SingHealth, Partnership, Boehringer, Doctor of Philosophy, Neoplasm, Infection, Survival, Pharmacokinetics, Quality of life, Scar, PDE4B, Inflammation, DSM-IV codes, Lung, Pulmonary fibrosis, Boehringer Ingelheim, Duke–NUS Medical School, Fibrosis, Death, Discovery, Patient, Vicki Belo, Circulatory system, Biology, Liver, IPF, Safety, Pharmaceutical industry

Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.

Key Points: 
  • Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.
  • The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte.
  • ‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues.
  • Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis.

RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence

Retrieved on: 
Friday, April 21, 2023
Data management, Systematic review, Partnership, Boehringer, Prevalence, Life, Geographic atrophy, Research, Retina, GA, Biomarker, Paratriathlon, Meta-analysis, Boehringer Ingelheim, Ophthalmology, Discovery, The Lancet, HIV disease progression rates, Artificial intelligence, Diagnosis, AI, Trauma, Disease, Medical device, Pharmaceutical industry

BERN, Switzerland and BOSTON, April 21, 2023 (GLOBE NEWSWIRE) -- RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim.

Key Points: 
  • BERN, Switzerland and BOSTON, April 21, 2023 (GLOBE NEWSWIRE) -- RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim.
  • The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery® platform and AI tools with Boehringer Ingelheim’s research in retinal diseases.
  • GA is a progressive, advanced form of age-related macular degeneration and a leading cause of complete loss of sight, estimated to affect around 5 million people worldwide1.
  • RetinAI’s AI tools for identifying novel biomarkers will be tested for the analysis of Boehringer Ingelheim’s imaging datasets from clinical studies and real-world evidence to identify additional, novel biomarkers and predictors of disease progression.

Longeveron Appoints Wa’el Hashad as Chief Executive Officer

Retrieved on: 
Tuesday, February 28, 2023
David Berry (inventor), Marketing, Boehringer Ingelheim, Eli Lilly and Company, Biotechnology, Therapy, MSC, Boehringer, University, Strategic Advisory Board for Intellectual Property Policy, Amgen, Drug development, Interim, Plasma protein binding, Eli Lilly, FDA, Metabolic disorder, Neuroscience, Medication, Growth, Fortune 500, American University in Cairo, Hypoplastic left heart syndrome, Washington State University College of Pharmacy and Pharmaceutical Sciences, Food and Drug Administration, Central Waqf Council, International business, Food, Otsuka Pharmaceutical, Pharmaceutical industry, Management, Pharmacy, Shimaa Hashad

MIAMI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for rare pediatric disease, aging-related conditions, and unmet medical needs, today announced the appointment of seasoned global pharmaceutical leader Wa’el Hashad as Chief Executive Officer. Mr. Hashad will assume the role of Chief Executive Officer effective March 1, 2023. Following Mr. Hashad joining Longeveron, current Interim Chief Executive Officer Chris Min, M.D., Ph.D., will continue in his role as Chief Medical Officer.

Key Points: 
  • Mr. Hashad will assume the role of Chief Executive Officer effective March 1, 2023.
  • Following Mr. Hashad joining Longeveron, current Interim Chief Executive Officer Chris Min, M.D., Ph.D., will continue in his role as Chief Medical Officer.
  • “The Board and I are delighted to welcome Mr. Hashad to Longeveron to lead the company through its next stage of growth.
  • Prior to Avanir, Mr. Hashad was Executive Vice President and Chief Commercial Officer at Seres Therapeutics, where he established the company’s launch and marketing strategy for microbiome-based therapies.

Modular Content Powers Omnichannel Engagement at Speed and Scale

Retrieved on: 
Thursday, February 16, 2023
Align Biopharma, Veeva Systems, Novo Nordisk, Boehringer Ingelheim, MLR, NYSE, Patient, Boehringer, Marketing, Creativity, Mobile phone, Moderna

PLEASANTON, Calif., Feb. 16, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that biopharmas are leveraging Veeva Vault PromoMats for modular content to accelerate medical, legal, and regulatory (MLR) reviews and drive more impactful engagement across channels and regions. With eight of the top 10 biopharmas using Vault PromoMats for modular content, and over 20 emerging companies starting to set a foundation, the industry is making the push to digital to deliver personalized, compliant content faster, and at scale.

Key Points: 
  • "Our customers are at the forefront of digital marketing, paving the way with new modular strategies for more scalable and effective content," said Pooja Ojala, vice president of commercial content at Veeva.
  • Partnering with customers across more than 35 countries to establish a modular content foundation, Vault PromoMats is helping teams quickly reuse content and bridge the gap across channels and geographies.
  • Based on early indicators, a modular content approach is helping one customer reduce time to market by more than 50%.
  • "Reusing pre-approved content modules and tailoring relevant content is crucial to our modular content strategy as we customize more memorable, omnichannel experiences," said Jason Benagh, director of global marketing operations at Moderna.

Modular Content Powers Omnichannel Engagement at Speed and Scale

Retrieved on: 
Thursday, February 16, 2023
Align Biopharma, Veeva Systems, Novo Nordisk, Boehringer Ingelheim, MLR, NYSE, Patient, Boehringer, Marketing, Creativity, Mobile phone, Moderna

BARCELONA, Spain, Feb. 16, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that  biopharmas are leveraging Veeva Vault PromoMats for modular content to accelerate medical, legal, and regulatory (MLR) reviews and drive more impactful engagement across channels and regions. With eight of the top 10 biopharmas using Vault PromoMats for modular content, and over 20 emerging companies starting to set a foundation, the industry is making the push to digital to deliver personalized, compliant content faster, and at scale.

Key Points: 
  • "Our customers are at the forefront of digital marketing, paving the way with new modular strategies for more scalable and effective content," said Pooja Ojala, vice president of commercial content at Veeva.
  • Partnering with customers across more than 35 countries to establish a modular content foundation, Vault PromoMats is helping teams quickly reuse content and bridge the gap across channels and geographies.
  • Based on early indicators, a modular content approach is helping one customer reduce time to market by more than 50%.
  • "Reusing pre-approved content modules and tailoring relevant content is crucial to our modular content strategy as we customize more memorable, omnichannel experiences," said Jason Benagh, director of global marketing operations at Moderna.